Worth checking the slide presentation again. The results are...

Worth checking the slide presentation again. The results are compelling and with such broad potential. Efti isn’t a one trick pony, it’s a master key.

Immutep CEO, Marc Voigt commented: “The combination of the OS data in the prespecified subgroups, immune monitoring data and Quality of Life data, which were all statistically significant, give us confidence as we move forward with the development of efti in various late-stage settings. The results here are particularly noteworthy because Her2-HR+ metastatic breast cancer is not a particularly immunogenic tumour and so does not always respond to treatment with modern immunotherapies such as anti-PD-1 therapy. Indeed, we have seen across our various studies that efti, with its unique mechanism of action, has the potential to benefit many cancer patients, including those with more limited treatment options.”

There’s an investment window and opportunity here that is remarkable. I don’t think it’s going stay open for long.

dyor